Niclas Rudolfson

Junior doctor and PhD candidate @lunduniversity, formerly of @harvardmed @HarvardPGSSC

[Niclas Rudolfson @N_Rudolfson]

@DoktorSalo Varierar rätt kraftigt med tid från symtomdebut som jag förstått det

[Niclas Rudolfson @N_Rudolfson]

@isabelfulcher Lubridate has a locale option you could try, should parse dates more or less automatically

[Constance Crozier @clcrozier]

I spent a humiliating amount of time learning how to make animated graphs, just to illustrate a fairly obvious point.

“Forecasting s-curves is hard”

My views on why carefully following daily figures is unlikely to provide insight.

https://t.co/yrE71bUXVT

[Vinay Prasad MD MPH @VPrasadMDMPH]

I want remdesivir to succeed

Today’s report from Chicago is not proof of benefit

Rct of remdesivir v standard of care endpoint survival OR

Rct remdesivir v placebo endpoint 7pt scale

If you dont produce this data, many will remain critical

We want Rx that work not snakeoil

[Vinay Prasad MD MPH @VPrasadMDMPH]

Most hypotheses-- gorgeous, eloquent, marvelous hypotheses-- fail in rigorous testing

Most swings in the dark connect with air

Come on, the chance that these maneuvers are going to yield success is vanishingly low, even if rationale is sound

[Vinay Prasad MD MPH @VPrasadMDMPH]

What has happened to us, docs?

Yes, we are scared, and yes there is uncertainty, but you don't walk away from decades of VTE guidance, decades of vent management, decades of guiding principles for experimental drugs based on a hunch, a guess, fragmented data, a preprint

[Vinay Prasad MD MPH @VPrasadMDMPH]

Ok, here is a little #Tweetorial about #COVID19 and whether, outside of a controlled trial, we should be using different:
1. rules for anti-coagulation/ lytics
2. ventilatory settings in ARDS
3. anti-virals/ anti-inflammatories

[Niclas Rudolfson @N_Rudolfson]

@JohnMeara You are absolutely right. So essentially, to get good indicator 1 data we will have to: 1. assess surgical capacity, and 2. adjust GIS models

[Niclas Rudolfson @N_Rudolfson]

Glad to present the results of our latest study, in which we compared patient reported travel times in rural Rwanda to the GIS models which have been used to derive 2-hour access to surgery. We conclude current GIS models likely overestimate geo access
https://t.co/MuD3WtRvCC 1/7

[Niclas Rudolfson @N_Rudolfson]

@gustafdrevin Can't say that I'm too surprised either. Certainly that's what a lot of people have thought, but now we have some harder data (and something to cite 😉)

[Harvard Global Surgery @HarvardPGSSC]

Check out our team’s latest publication on validating the global surgery indicator on geographic access to surgical care @WorldJSurg https://t.co/A6VfYT9NBS. @BHedtGauthier @robertriviello @N_Rudolfson @LeniGruendl @HarvardPGSSC @JohnMeara

[Niclas Rudolfson @N_Rudolfson]

Proud to have worked alongside great team consisting of @LeniGruendl @Theonkurunziza @robertriviello @BHedtGauthier @HarvardPGSSC and others! 7/7

[Niclas Rudolfson @N_Rudolfson]

How does this affect NSOAPS? @JohnMeara @AndyLeather1 @LarsHagander @VatshalanS @markshrime @emakasa 6/7

[Maarten van Smeden @MaartenvSmeden]

We need less COVID-19 research, better COVID-19 research and COVID-19 research done for the right reasons

[Jonas Ekström @DrEkstrom]

Dear American friends! Since we’ve received a lot of attention lately, I would like to give you some facts and figures on the ’situation in Sweden’ regarding the #coronavirus and #covid19.

[Bethany Hedt-Gauthier, PhD @BHedtGauthier]

I also have to remind myself that access to high-quality, safe cesarean deliveries is still and will continue to be important. So while it feels odd to write that grant now, and while I have great concerns that anything not-COVID will be funded. That is what I am working on.